Want to see TSE:GLOW full AI Analyst Report?
Glow LifeTech (GLOW) AI Stock Analysis
Glow LifeTech
(CNQX:GLOW)
The score is primarily constrained by continued negative margins and ongoing cash burn despite improving revenue and narrowing losses. Technical signals are neutral-to-soft with slightly negative momentum, and valuation is weakened by a negative P/E with no dividend yield support.
Glow LifeTech (GLOW) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 7.70M
- Dividend Yield
- ―
- Average Volume (3M)
- 133.10K
- Price to Earnings (P/E)
- -50.0
- Beta (1Y)
- -0.03
- Revenue Growth
- 56.41%
- EPS Growth
- 91.30%
- Country
- Canada
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Glow LifeTech Business Overview & Revenue Model
Company Description
Glow Lifetech Corp. is a biotechnology enterprise based in North America, dedicated to the development and marketing of nutraceutical and cannabinoid-derived products. The company is actively commercializing two core technologies: MyCell Enhanced tec...
Glow LifeTech Financial Statement Overview
Summary
Revenue is scaling and losses have narrowed materially, but profitability remains negative (TTM net margin ~-13%, operating margin ~-17%) and cash generation is still weak with negative operating and free cash flow.
Income Statement
44NeutralBalance Sheet
63PositiveCash Flow
38Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Jun 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.31M | 2.05M | 836.19K | 43.93K | 0 | 0 |
| Gross Profit | 366.15K | 346.11K | 591.00K | -759.18K | -263.26K | -43.39K |
| EBITDA | -149.62K | -471.01K | -1.24M | -1.31M | -1.92M | -4.59M |
| Net Income | -296.77K | -617.86K | -2.66M | -1.59M | -2.24M | -11.31M |
Balance Sheet | ||||||
| Total Assets | 4.18M | 3.92M | 3.72M | 1.91M | 2.31M | 3.76M |
| Cash, Cash Equivalents and Short-Term Investments | 1.60M | 1.37M | 1.29M | 34 | 75.19K | 746.02K |
| Total Debt | 34.51K | 56.19K | 404.08K | 171.75K | 147.36K | 39.93K |
| Total Liabilities | 1.11M | 1.21M | 1.15M | 2.35M | 1.14M | 328.03K |
| Stockholders Equity | 3.07M | 2.71M | 2.57M | -433.12K | 1.16M | 3.44M |
Cash Flow | ||||||
| Free Cash Flow | -164.61K | -118.20K | -1.36M | -490.86K | -1.36M | -3.62M |
| Operating Cash Flow | -137.36K | -15.03K | -1.35M | -417.26K | -1.30M | -3.18M |
| Investing Cash Flow | -11.62K | -102.18K | 16.70K | -60.91K | 18.31K | -541.41K |
| Financing Cash Flow | 684.60K | 191.39K | 2.62M | 445.01K | 491.44K | 4.59M |
Glow LifeTech Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GLOW, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 47.85 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:GLOW.
Glow LifeTech Peers Comparison
Overall Rating
TSE:MDMA50Neutral- TSE:GLOW45Neutral
TSE:PREV44Neutral
TSE:CSCI42Neutral
TSE:KNE37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:MDMA | 50Neutral | CAD 18.57M | -11.41 | -72.15% | ― | 224.46% | 28.37% |
| TSE:GLOW | 45Neutral | CAD 7.70M | -50.00 | -10.61% | ― | 56.41% | 91.30% |
| TSE:PREV | 44Neutral | CAD 12.76M | -16.67 | 10.15% | ― | ― | -36.36% |
| TSE:CSCI | 42Neutral | CAD 8.37M | -0.46 | -48.52% | ― | -13.00% | 75.31% |
| TSE:KNE | 37Underperform | CAD 6.15M | -2.05 | 273.53% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:GLOW | Glow Lifetech Corp | 0.04 | -0.01 | -20.00% | |
| TSE:CSCI | Cosciens Biopharma Inc. | 8.40 | -2.31 | -21.57% | |
| TSE:KNE | Kane Biotech | 0.03 | 0.00 | 0.00% | |
| TSE:QPT | Quest Pharmatech | 0.02 | -0.02 | -50.00% | |
| TSE:PREV | PreveCeutical Medical | 0.02 | -0.01 | -33.33% | |
| TSE:MDMA | PharmAla Biotech Holdings, Inc. | 0.17 | 0.05 | 41.67% |
Glow LifeTech Corporate Events
Glow Lifetech Extends Growth Streak and Accelerates National Cannabis Expansion
PositiveGlow Lifetech reported a strong second quarter for 2026, posting its 12th consecutive period of year-over-year revenue growth, sustained high gross margins and positive operating cash flow, while cutting total expenses by 29 percent. The company also...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026